type
interferon
ifn
compris
famili
cytokin
signal
common
cellular
receptor
induc
plethora
gene
antivir
activ
recombin
ifn
use
treatment
hepat
c
viru
infect
multipl
sclerosi
certain
malign
capabl
type
ifn
suppress
viru
replic
result
cytopath
effect
frequent
use
measur
bioactiv
howev
assay
timeconsum
requir
appropri
biosafeti
contain
studi
improv
ifn
assay
present
base
recombin
vesicular
stomat
viru
vsv
replicon
encod
two
report
protein
firefli
luciferas
green
fluoresc
protein
vector
lack
essenti
envelop
glycoprotein
g
gene
vsv
propag
g
proteinexpress
transgen
cell
line
sever
mammalian
avian
cell
turn
suscept
infect
complement
replicon
particl
infect
cell
readili
express
report
protein
high
level
five
hour
post
infect
human
fibroblast
treat
serial
dilut
human
ifnb
prior
infect
report
express
accordingli
suppress
method
sensit
faster
classic
ifn
bioassay
base
vsv
cytopath
effect
addit
antivir
activ
human
ifnl
type
iii
ifn
determin
cell
ifnb
ifnl
acidst
ifnb
resist
alkalin
treatment
antivir
activ
canin
porcin
avian
type
ifn
analys
cell
line
deriv
correspond
speci
safe
bioassay
use
rapid
sensit
quantif
multispeci
type
ifn
potenti
antivir
cytokin
citat
berger
rentsch
zimmer
g
vesicular
stomat
viru
repliconbas
bioassay
rapid
sensit
determin
multispeci
type
interferon
plo
one
ifna
ifnb
structur
relat
cytokin
type
interferon
famili
mediat
earli
innat
immun
respons
viral
infect
distinct
ifna
gene
present
human
genom
singl
gene
encod
ifnb
gene
transcript
activ
cell
sens
viru
infect
pattern
recognit
receptor
retino
acid
induc
gene
rigi
helicas
follow
secret
ifna
ifnb
act
similarli
bind
common
ubiquit
express
ifnab
receptor
result
activ
jakstat
signal
transduct
pathway
transcript
ifninduc
gene
sever
gene
encod
protein
strong
antivir
activ
ie
mx
protein
protein
kinas
r
synthetas
due
autocrin
action
type
ifn
may
attenu
viru
replic
infect
cell
probabl
import
paracrin
action
type
ifn
induc
antivir
state
previous
uninfect
cell
therebi
block
viru
dissemin
organ
addit
classic
antivir
function
type
ifn
known
affect
cell
prolifer
differenti
modul
immun
respons
inhibit
angiogenesi
promot
apoptosi
genet
engin
type
ifn
current
clinic
use
treatment
multipl
sclerosi
chronic
hepat
c
viru
infect
certain
type
cancer
issu
increas
import
determin
neutral
antibodi
induc
patient
follow
recombin
ifn
therapi
apart
ifnab
cytokin
ifnc
type
ii
ifn
ifnl
type
iii
ifn
exhibit
antivir
activ
although
bind
distinct
receptor
particular
type
iii
ifn
induc
transcript
activ
antivir
gene
similar
activ
type
ifn
type
iii
ifn
act
primarili
epitheli
cell
probabl
play
import
role
innat
immun
respons
epitheli
tissu
viru
infect
accur
determin
antivir
ifn
activ
cumbersom
issu
classic
bioassay
serial
dilut
test
sampl
unknown
ifn
activ
type
ifn
standard
incub
appropri
cell
line
prior
infect
cytolyt
viru
vesicular
stomat
viru
vsv
encephalomyocard
viru
sendai
viru
reciproc
valu
highest
type
ifn
dilut
mediat
protect
cell
virusinduc
cytopath
effect
cpe
defin
one
unit
type
ifn
per
volum
classic
ifn
bioassay
timeconsum
cpe
normal
need
hour
develop
faster
readout
achiev
recombin
virus
express
report
protein
green
fluoresc
protein
gfp
firefli
luciferas
howev
work
live
viru
requir
appropri
biosafeti
contain
exampl
recent
publish
ifn
bioassay
perform
biosafeti
level
facil
test
make
use
recombin
rift
valley
fever
viru
viral
repliconbas
bioassay
take
advantag
disabl
propagationincompet
virus
may
provid
attract
altern
live
virusbas
bioassay
human
hepatoma
cell
line
harbour
select
hepat
c
viru
replicon
success
employ
measur
type
ifn
patient
chronic
hepat
c
viru
infect
howev
type
ifn
act
speciesdepend
manner
system
may
applic
anim
ifn
transgen
cell
line
express
report
gene
control
ifnrespons
promot
may
also
use
determin
ifn
activ
biosaf
condit
howev
difficult
simpli
relat
transcript
report
gene
activ
antivir
activ
report
novel
type
ifn
bioassay
present
base
vsv
replicon
particl
assay
highli
sensit
quantifi
due
express
firefli
luciferas
report
gene
addit
assay
rapidli
perform
within
hour
may
use
determin
antivir
activ
ifn
human
well
speci
thu
bioassay
may
gener
interest
want
determin
antivir
activ
cytokin
type
ifn
cell
cell
obtain
german
cell
cultur
collect
dszm
braunschweig
germani
grown
earl
minim
essenti
medium
emem
supplement
fetal
bovin
serum
fb
transgen
cell
clone
express
vsv
g
protein
regul
manner
maintain
describ
previous
porcin
kidney
cell
line
atcc
manassa
va
propag
dulbecco
modifi
eagl
medium
supplement
nonessenti
amino
acid
mm
napyruv
hors
serum
canin
osteosarcoma
cell
atcc
human
lung
adenocarcinoma
cell
atcc
nhdf
normal
human
dermal
fibroblast
lonza
cologn
germani
maintain
emem
fb
chicken
fibroblast
cell
line
atcc
maintain
dulbecco
modifi
eagl
medium
fb
cell
line
cultur
humidifi
atmospher
contain
co
except
cell
kept
balb
fibroblast
subclon
kindli
provid
n
pringl
univers
colleg
london
uk
maintain
dulbecco
modifi
eagl
medium
human
murin
ifnb
human
ifnl
purchas
pbl
interferonsourc
piscataway
nj
recombin
porcin
kindli
provid
nicola
ruggli
ivi
usern
switzerland
recombin
chicken
ifna
kindli
provid
peter
heli
univers
freiburg
germani
canin
ifnb
kindli
provid
philipp
plattet
depart
clinic
research
veterinari
public
health
univers
bern
plasmidbas
rescu
system
use
gener
gdelet
vsv
drive
express
firefli
luciferas
egfp
previous
describ
genom
plasmid
pvsv
dg
ha
contain
distinct
transcript
unit
npmhaegfpl
modifi
replac
influenza
viru
ha
gene
fourth
posit
egfp
take
advantag
mlui
bsteii
endonucleas
restrict
site
upstream
downstream
ha
orf
respect
firefli
luciferas
gene
amplifi
pbil
plasmid
clontech
pfu
pcr
insert
fifth
transcrit
unit
use
xhoi
nhei
endonucleas
restrict
site
result
plasmid
design
pvsv
dg
luc
contain
gene
order
npmegfplucl
fig
gener
vsv
dg
luc
replicon
particl
helper
cell
grown
diamet
cultur
dish
confluenc
infect
recombin
modifi
vaccinia
viru
ankara
pfu
per
cell
express
rna
polymeras
gift
gerd
sutter
germani
classifi
german
central
committe
biosafeti
organ
refer
number
nineti
minut
post
infect
medium
replac
fresh
emem
contain
fb
mifepriston
sigmaaldrich
buch
switzerland
induc
vsv
g
express
subsequ
cell
transfect
mg
pvsv
dg
luc
mg
mg
mg
use
lipofectamin
tm
transfect
reagent
invitrogen
basel
switzerland
cell
trypsin
hour
post
transfect
seed
flask
along
equal
number
fresh
cell
cell
incub
hour
presenc
mifepriston
cell
cultur
supernat
clarifi
lowspe
centrifug
pass
size
filter
deplet
vaccinia
viru
vsv
dg
luc
propag
mifepristoneinduc
cell
store
frozen
determin
infecti
viru
titer
confluent
grown
microtit
plate
inocul
duplic
ml
serial
tenfold
viru
dilut
h
well
addit
receiv
ml
emem
incub
h
infecti
titer
calcul
accord
number
gfpexpress
cellswel
express
fluorescenceform
unit
per
millilit
ffuml
titrat
cell
grown
microtit
plate
cell
inocul
tenfold
serial
viru
dilut
min
overlay
medium
contain
methylcellulos
follow
incub
h
cell
fix
paraformaldehyd
permeabil
triton
subsequ
incub
monoclon
antibodi
direct
vaccinia
protein
kindli
provid
jonathan
yewdel
nih
bethesda
usa
antimous
igg
conjug
horseradish
peroxidas
dako
infect
cell
foci
visual
aec
peroxidas
substrat
express
plaqueform
unit
per
millilit
pfuml
use
assay
final
vsv
replicon
particl
prepar
prove
free
serial
twofold
fourfold
dilut
type
ifn
prepar
cell
cultur
medium
contain
fb
ifn
dilut
ml
ad
quadrupl
confluent
cell
grown
cellswel
incub
either
hour
cell
cell
line
cell
infect
vsv
dg
luc
moi
incub
hour
medium
aspir
ml
luciferas
lysi
buffer
biotium
inc
hayward
ca
ad
cell
cell
lysat
store
firefli
luciferas
activ
determin
centro
lb
luminomet
berthold
technolog
luminesc
record
follow
inject
ml
dluciferin
substrat
biotium
white
plate
contain
aliquot
cell
lysat
rel
antivir
activ
calcul
accord
follow
formula
antivir
activ
rlu
ifn
blank
rlu
blank
mockinfect
cell
lysat
serv
blank
rel
light
unit
rlu
detect
sampl
subtract
read
taken
vsv
dg
luc
infect
cell
lysat
rlu
ifn
repres
rlu
valu
ifntreat
cell
rlu
read
taken
refer
cell
receiv
type
ifn
convent
type
ifn
bioassay
perform
incub
cell
cultur
hour
twofold
dilut
type
ifn
describ
cell
infect
propagationcompet
vsv
moi
pfucel
incub
cytopath
effect
cpe
evid
mocktreat
control
cell
cell
wash
twice
pb
stain
h
crystal
violet
formalin
plate
wash
tap
water
remov
excess
crystal
violet
dri
dye
dissolv
ad
ml
ethanol
well
absorb
crystal
violet
nm
determin
micropl
reader
ifn
titer
calcul
reciproc
last
ifn
dilut
caus
inhibit
virusinduc
cpe
reduct
absorb
nm
compar
mockinfect
cell
express
ifn
unit
per
volum
altern
antivir
activ
calcul
accord
follow
formula
antivir
activ
ifn
mock
ifn
repres
absorb
ifntreat
nontreat
cell
follow
infect
vsv
stain
crystal
violet
respect
mock
denot
absorb
noninfect
cell
mean
valu
standard
deviat
calcul
statist
analysi
perform
use
pair
student
ttest
consid
signific
previous
vsv
replicon
vector
gener
replac
glycoprotein
g
gene
vsv
hemagglutinin
ha
gene
influenza
viru
insert
extra
transcript
unit
hal
intergen
junction
drive
express
modifi
gfp
gene
present
work
vector
modifi
insert
firefli
luciferas
gene
transcript
unit
posit
therebi
replac
gfp
gene
exchang
ha
gene
gfp
gene
fig
result
vector
vsv
dg
luc
propag
helper
cell
express
vsv
g
protein
induc
manner
viru
replicon
particl
vrp
releas
cell
cultur
supernat
h
post
infect
data
shown
sever
mammalian
avian
cell
found
suscept
infect
vrp
line
previou
observ
broad
cell
tropism
vsv
infect
cell
readili
detect
h
post
infect
mean
gfp
report
express
fig
howev
nonhelp
cell
unabl
complement
vsv
g
delet
thu
could
produc
infecti
progeni
viru
importantli
vsv
dg
luc
induc
type
ifn
cell
line
analys
data
shown
ascrib
host
shutoff
activ
vsv
matrix
protein
infect
cell
vsv
dg
luc
use
multipl
infect
moi
ffucel
result
increas
firefli
luciferas
report
activ
time
fig
subsequ
experi
luciferas
activ
gener
record
h
post
infect
signaltonois
ratio
suffici
high
time
cell
infect
differ
viru
dose
rate
luciferas
report
activ
increas
linearli
ffucel
fig
luciferas
report
activ
vsv
dg
luc
infect
cell
depend
replicationtranscript
level
rna
replicon
thu
reduct
viral
genom
replic
consequ
type
ifn
action
lead
correspondingli
lower
luciferas
level
test
hypothesi
normal
human
dermal
fibroblast
nhdf
incub
variou
time
period
serial
dilut
human
ifnb
infect
vsv
dg
luc
dosedepend
effect
ifnb
firefli
luciferas
report
activ
observ
hour
incub
fig
unit
ifnb
led
suppress
luciferas
activ
extend
incub
time
hour
improv
sensit
test
ifn
unit
rang
howev
cell
treat
hour
dose
respons
curv
significantli
shift
lower
ifn
unit
p
unit
rang
approxim
unit
ifnb
suffici
suppress
report
activ
result
indic
ifnbinduc
antivir
state
nhdf
cell
detect
earli
hour
addit
ifnb
although
sensit
assay
higher
cell
incub
ifnb
prolong
time
vsv
dg
luc
also
use
quantifi
activ
porcin
chicken
ifna
dose
respons
curv
chicken
ifna
chicken
fibroblast
fig
similar
one
human
ifnb
nhdf
fig
porcin
ifna
show
differ
kinet
porcin
kidney
cell
cell
full
antivir
state
accomplish
hour
treatment
indic
cell
respond
rather
slowli
action
type
ifn
fig
thu
assay
applic
type
ifn
differ
speci
may
perform
differenti
distinct
cell
type
evalu
bioassay
sampl
contain
type
ifn
unknown
activ
test
commerci
ifnb
standard
result
compar
obtain
convent
ifn
bioassay
base
vsv
cytotox
human
type
ifn
induc
nhdf
human
fibroblast
follow
infect
vsv
q
propagationcompet
viru
express
mutant
matrix
protein
unabl
block
nucleocytoplasm
rna
transport
cell
sampl
test
antivir
activ
vsv
q
inactiv
min
hcl
avoid
interfer
bioassay
see
also
section
thermal
ph
stabil
ifn
vsv
dg
luc
replicon
bioassay
use
pgml
commerci
ifnb
standard
result
antivir
activ
consider
final
dilut
produc
antivir
activ
type
ifn
concentr
two
test
sampl
defin
pgml
pgml
respect
fig
sampl
test
convent
bioassay
fig
valu
rang
pgml
indic
assay
princip
agre
nevertheless
repliconbas
bioassay
prove
sensit
convent
one
lower
amount
type
ifn
suffici
reduc
luciferas
report
activ
compar
curv
shown
fig
fig
speciesdepend
action
type
ifn
analys
incub
human
canin
murin
chicken
cell
hour
unit
type
ifn
either
homolog
speci
differ
one
cell
treat
respect
homolog
ifn
antivir
state
induc
indic
lack
gfp
express
hour
post
infect
vsv
dg
luc
fig
contrast
untreat
cell
cell
receiv
type
ifn
differ
speci
protect
show
gfp
express
accordingli
compar
effect
differ
concentr
homolog
heterolog
type
ifn
human
cell
treat
nhdf
hour
serial
dilut
human
porcin
murin
type
ifn
prior
infect
vsv
dg
luc
firefli
luciferas
report
activ
infect
cell
lysat
indic
porcin
ifna
activ
nhdf
albeit
reduc
level
compar
human
ifnb
fig
p
unit
rang
murin
ifnb
show
even
lower
activ
nhdf
ed
unit
per
nhdf
cell
p
unit
rang
result
demonstr
type
ifn
act
speciesdepend
manner
accentu
need
select
appropri
cell
line
determin
activ
often
encount
problem
activ
type
ifn
determin
sampl
contain
live
viru
viru
infect
may
interfer
bioassay
inactiv
assay
perform
preferenti
without
touch
activ
type
ifn
mani
virus
simpli
inactiv
treatment
heat
first
analys
thermal
stabil
human
ifnb
use
vsv
dg
luc
bioassay
antivir
activ
human
ifnb
fulli
maintain
cytokin
incub
min
fig
activ
preserv
p
activ
human
ifnb
drop
p
incub
higher
temperatur
affect
activ
drastic
although
activ
still
left
temperatur
human
ifnb
heat
min
activ
complet
abolish
contrast
human
ifnb
porcin
ifna
complet
inactiv
wherea
human
ifnl
type
iii
ifn
show
even
higher
residu
activ
suggest
cytokin
differ
physicochem
properti
studi
sensit
type
type
iii
ifn
condit
extrem
ph
human
ifnb
human
ifnl
treat
min
either
hcl
naoh
h
adjust
neutral
ph
assay
nhdf
cell
respect
turn
antivir
activ
human
ifnb
significantli
affect
acid
fig
confirm
previous
note
acidst
type
ifn
ifnl
show
similar
properti
antivir
activ
maintain
follow
treatment
hcl
fig
contrast
alkalin
treatment
significantli
reduc
activ
ifnl
ngml
rang
wherea
ifnb
affect
fig
thu
treatment
acid
may
employ
inactiv
viru
test
sampl
without
affect
activ
type
type
iii
ifn
hand
alkalin
may
use
differenti
type
type
iii
ifn
convent
bioassay
take
advantag
antivir
activ
type
ifn
measur
inhibit
virusinduc
cytopath
effect
cell
cultur
studi
present
improv
bioassay
employ
recombin
vsv
replicon
equip
two
report
protein
assay
prove
advantag
convent
assay
respect
biosafeti
sensit
time
requir
use
cytopath
virus
convent
type
ifn
bioassay
make
appropri
biosafeti
measur
necessari
reduc
risk
unwant
viru
transmiss
infect
regard
vsv
dg
luc
replicon
particl
regard
biosaf
sinc
modifi
vsv
genom
lack
envelop
glycoprotein
g
gene
vsv
dg
luc
propag
helper
cell
provid
g
glycoprotein
tran
replicon
particl
produc
cell
run
singl
cycl
infect
produc
infecti
progeni
anoth
aspect
contribut
biosafeti
rna
replicon
replic
exclus
cytosol
produc
cdna
intermedi
thu
case
accident
infect
risk
recombin
integr
host
chromosom
dna
exclud
viru
prepar
use
ifn
bioassay
must
contain
type
ifn
may
distort
result
addit
virus
induc
ifn
infect
report
cell
assur
effect
measur
sole
due
exogen
ifn
ad
criteria
fulfil
vsv
dg
luc
helper
cell
use
propag
replicon
particl
deriv
cell
defect
synthesi
type
ifn
addit
vsvdg
replicon
induc
type
ifn
infect
report
cell
vsv
matrix
protein
effici
block
nuclear
export
cellular
mrna
includ
ifn
mrna
convent
type
ifn
bioassay
often
take
hour
complet
reli
inhibit
cytopath
effect
contrast
bioassay
present
take
advantag
firefli
luciferas
report
detect
high
sensit
long
cytopath
effect
appar
although
luciferas
report
enabl
us
unambigu
quantifi
ifnmedi
reduct
viru
replic
frequent
observ
standard
deviat
antivir
activ
increas
cell
treat
low
amount
type
ifn
like
reflect
high
report
gene
express
low
level
type
ifn
inaccuraci
associ
pipet
small
volum
ml
engag
common
cellular
receptor
type
ifn
lead
activ
jakstat
pathway
transcript
induct
sever
gene
antivir
activ
common
practic
cell
incub
type
ifn
sever
hour
induc
antivir
state
find
suggest
antivir
state
detect
much
earlier
exampl
treatment
nhdf
unit
human
ifnb
hour
subsequ
infect
vsv
dg
luc
hour
suffici
suppress
firefli
report
express
even
though
effect
dose
lower
longer
incub
time
fibroblast
respond
chicken
ifna
dose
respons
kinet
similar
one
observ
human
ifnb
nhdf
cell
respond
porcin
type
ifn
much
slower
way
thu
compar
convent
bioassay
vsv
dg
luc
may
allow
quantif
type
ifn
consider
shorter
time
provid
appropri
cell
line
select
select
suitabl
cell
line
also
import
respect
speci
deriv
full
activ
type
ifn
observ
cell
correspond
speci
sinc
vsv
abl
infect
broad
spectrum
mammalian
avian
cell
new
bioassay
may
use
determin
bioactiv
type
ifn
mani
differ
anim
although
type
ifn
predomin
cytokin
antivir
activ
exclud
test
sampl
contain
cytokin
inhibit
vsv
replic
inde
use
vsv
dg
luc
replicon
assay
possibl
quantifi
antivir
activ
ifnl
type
iii
ifn
rais
import
question
distinguish
differ
antivir
cytokin
certainli
neutral
antibodi
may
employ
specifi
antivir
cytokin
present
sampl
addit
extraordinari
acidst
type
ifn
may
use
differenti
acidlabil
cytokin
type
ii
ifn
howev
acid
may
use
distinguish
type
type
iii
ifn
ifnl
prove
acidst
well
sinc
ifnl
ifnb
sensit
naoh
treatment
alkalin
may
use
instead
howev
condit
treatment
still
optim
guarante
complet
inactiv
type
iii
ifn
maintain
activ
type
ifn
addit
antivir
cytokin
test
sampl
may
also
contain
unknown
virus
potenti
interfer
bioassay
treatment
heat
acid
may
use
inactiv
virus
without
affect
bioactiv
type
type
iii
ifn
howev
heatinactiv
influenza
virus
still
may
abl
induc
type
ifn
viru
inactiv
acid
may
conveni
correct
reliabl
determin
type
ifn
biolog
activ
import
issu
new
bioassay
present
studi
repres
attract
altern
convent
type
ifn
bioassay
work
cytotox
live
virus
vsv
dg
luc
easili
produc
handl
condit
activ
replicon
easili
determin
standard
take
advantag
two
report
protein
may
store
prolong
time
lyophil
form
without
lose
activ
final
proven
sensit
rapid
accur
assay
recommend
determin
type
ifn
number
mammalian
avian
speci
final
test
may
develop
quantifi
antivir
activ
cytokin
type
ii
type
iii
ifn
